Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Norwich Pharmaceuticals
Expanded Phase I Capabilities and Tech Transfers Lead to New Business
NORWICH, N.Y., Oct. 16, 2013 /PRNewswire/ -- Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry, announced today a surge in new business awards in the second half of 2013. Specialty pharma companies make up the majority of Norwich's new clientele along with one European-based large pharma. Additional new projects are pending.
"Norwich's business growth in the second half of the year can be attributed to our newly expanded Phase I development capabilities and our Synchronized Outsourced Solutions service offering," said Terry Novak, president of Norwich. "Over the past year, Norwich has added state-of-the-art technologies and our more robust capabilities that make us the only service provider capable of offering contract development, clinical research and manufacturing solutions synchronized for a product's entire lifespan."
In addition to the new services, Norwich will also be providing many of its other industry-leading formulation and development services for the new projects including: extrusion/spheronization, mini-tablet compression, fluid bed coating and tablet coating.
About Norwich Pharmaceuticals
Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 125 years of experience and an unparalleled regulatory compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development, CTM manufacturing, full clinical trial services to scale-up and commercial manufacturing. Visit www.norwichpharma.com for more information.
©2012 PR Newswire. All Rights Reserved.